From the reviews: "The target audience ... is primarily researchers in the field of psychopharmacology of psychosis as well as interested psychiatrists and psychologists. ... This book will provide readers with the current research issues in the psychopharmacology of schizophrenia from a 'one disease' perspective." (Michael Joel Schrift, Doody's Book Reviews, March, 2013)